Phenotyping genetic differences in aldehyde dehydrogenase 2 after an alcohol challenge in humans - White, Joseph R.; Rwere, Freeborn; Zeng, Xiaocong; McNeil, Leslie; Zhou, Kevin; Angst, Martin S.; Chen, Che-Hong; Mochly-Rosen, Daria; Gross, Eric R. (medRxiv, 2020)
Inefficient aldehyde metabolism by an aldehyde dehydrogenase 2 (ALDH2) genetic variant, ALDH2*2 (rs671), increases the risk of esophageal cancer with alcohol consumption. Here we tested the hypothesis that additional genetic differences in ALDH2 besides ALDH2*2 exist resulting in inefficient acetaldehyde metabolism after alcohol consumption.Human volunteers were recruited who self-reported flushing after alcohol. The first stage recruited East Asians and the second stage non-East Asians. After phone screening and ALDH2 sequencing, volunteers were subjected to an alcohol challenge (0.25g/kg). Physiological parameters and breath acetaldehyde levels were assessed.Twenty-six participants were given an alcohol challenge. In the first stage, when comparing the ALDH2*1/*2 genotype to ALDH2*1/*1 genotype, tachycardia (104±3* versus 73±4 beats per minute), increases in facial skin temperature (99.6±0.4* versus 95.9±0.50F), and increases in breath acetaldehyde (peak: 2.1±0.4* versus 0.2±0.3ppm, n=8/group, *p<0.01) occurred after alcohol consumption. In the second stage, heterozygotes for an ALDH2 intron variant (rs4646777, G>A) caused increases in facial skin temperature (98±1* versus 94±10F, n=4, *p<0.01) without tachycardia or acetaldehyde accumulation after alcohol consumption. Subjects self-identifying as non-East Asian genotyped with an ALDH2*1/*2 variant also displayed a characteristic ALDH2*1/*2 phenotype after alcohol consumption. Further, ALDH2 point mutations rs747096195 (R101G) and rs190764869 (R114W) showed reduced acetaldehyde metabolism and increases in facial skin temperature after an alcohol challenge relative to wild type ALDH2 subjects.Taken together, we developed a method to non-invasively phenotype genetic differences for ALDH2 in humans including quantifying aldehyde metabolism in single subjects. We also discovered genetic differences besides ALDH2*2 that cause inefficient aldehyde metabolism.Brief Summary We developed a method to phenotype genetic differences in ALDH2 and we discovered novel ALDH2 mutations that result in inefficient acetaldehyde metabolism after alcohol consumption.Competing Interest StatementEric Gross holds a patent related to the ALDH2 activator Alda-1 and research funding from the National Institutes of Health. Daria Mochly-Rosen and Che-Hong Chen hold patents related to Alda-1. Dr. Angst is a consultant for Syneos Health, Hassard and Bonnington LLP, and has funding for a research study from Alkahest Inc. Additional authors have no disclosures. Clinical TrialPrior to recruitment and testing, IRB approval was obtained from Stanford University (IRB 46095). During IRB review, this study was identified as a basic experimental study involving humans with the manipulation or task used (consuming alcohol) expressly used for measurement and was not considered an intervention. As such, this was not considered a clinical trial.Funding StatementFunding for this project was supported by Stanford Chem-H (ERG and DMR), NIAAA AA011147 (DMR), and NIGMS GM119522 (ERG).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB approval was obtained from Stanford University under IRB 46095.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is presented within the manuscript and is freely available.